Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,435.60 17.92 0.12%
TOPIX 1,168.57 2.02 0.17%
HANG SENG 22,767.35 71.34 0.31%

BioMarin to Present at the Lazard Capital Markets Healthcare Conference



BioMarin to Present at the Lazard Capital Markets Healthcare Conference

SAN RAFAEL, Calif., Nov. 6, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive
Officer at BioMarin, will present a company update at the Lazard Capital
Markets Healthcare Conference in New York on Tuesday, November 13, 2012 at
4:00 p.m. ET.

Interested parties may access a live audio webcast of the conference call via
the investor section of the BioMarin website, www.BMRN.com. A replay of the
call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme^® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme^® (laronidase) for
mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a
50/50 joint venture with Genzyme Corporation; Kuvan^® (sapropterin
dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership
with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and
Firdapse™ (amifampridine), which has been approved by the European Commission
for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product
candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is
currently in Phase III clinical development for the treatment of MPS IVA,
amifampridine phosphate (3,4-diaminopyridine phosphate), which is currently in
Phase III clinical development for the treatment of LEMS in the U.S., PEG-PAL
(PEGylated recombinant phenylalanine ammonia lyase), which is currently in
Phase II clinical development for the treatment of PKU, BMN-701, a novel
fusion protein of insulin-like growth factor 2 and acid alpha glucosidase
(IGF2-GAA), which is currently in Phase I/II clinical development for the
treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase (PARP)
inhibitor, which is currently in Phase I/II clinical development for the
treatment of genetically-defined cancers, and BMN-111, a modified
C-nutriuretic peptide, which is currently in Phase I clinical development for
the treatment of achondroplasia. For additional information, please visit
www.BMRN.com. Information on BioMarin's website is not incorporated by
reference into this press release.

The BioMarin Pharmaceutical Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=11419

BioMarin^®, Naglazyme^®, Kuvan^® and Firdapse™ are registered trademarks of
BioMarin Pharmaceutical Inc.

Aldurazyme^® is a registered trademark of BioMarin/Genzyme LLC.

CONTACT: Investors and Media
         Eugenia Shen
         BioMarin Pharmaceutical Inc.
         (415) 506-6570

BioMarin Pharmaceutical Inc. Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement